Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?

Moderna (MRNA) is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of$1.91 per share, respectively. Both metrics indicate a significant decline from the year-ago levels.Estimates for Moderna’s 2024 loss per share have increased from $9.52 to$9.88 in the past 60 days. During the same period, estimates for 2025 loss per share have risen from $7.37 to$8.59. Image Source: Zacks Investment Re ...